GUTS
Price
$1.32
Change
-$0.07 (-5.00%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
182.27M
Intraday BUY SELL Signals
SPRB
Price
$111.16
Change
-$3.84 (-3.34%)
Updated
Nov 19, 04:58 PM (EDT)
Capitalization
118.81M
Intraday BUY SELL Signals
Interact to see
Advertisement

GUTS vs SPRB

Header iconGUTS vs SPRB Comparison
Open Charts GUTS vs SPRBBanner chart's image
Fractyl Health
Price$1.32
Change-$0.07 (-5.00%)
Volume$24.29K
Capitalization182.27M
Spruce Biosciences
Price$111.16
Change-$3.84 (-3.34%)
Volume$1K
Capitalization118.81M
GUTS vs SPRB Comparison Chart in %
GUTS
Daily Signal:
Gain/Loss:
SPRB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GUTS vs. SPRB commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GUTS is a Hold and SPRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (GUTS: $1.33 vs. SPRB: $111.00)
Brand notoriety: GUTS and SPRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GUTS: 41% vs. SPRB: 48%
Market capitalization -- GUTS: $182.27M vs. SPRB: $118.81M
GUTS [@Biotechnology] is valued at $182.27M. SPRB’s [@Biotechnology] market capitalization is $118.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GUTS’s FA Score shows that 0 FA rating(s) are green whileSPRB’s FA Score has 0 green FA rating(s).

  • GUTS’s FA Score: 0 green, 5 red.
  • SPRB’s FA Score: 0 green, 5 red.
According to our system of comparison, both GUTS and SPRB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GUTS’s TA Score shows that 4 TA indicator(s) are bullish while SPRB’s TA Score has 3 bullish TA indicator(s).

  • GUTS’s TA Score: 4 bullish, 6 bearish.
  • SPRB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, SPRB is a better buy in the short-term than GUTS.

Price Growth

GUTS (@Biotechnology) experienced а +17.70% price change this week, while SPRB (@Biotechnology) price change was +8.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GUTS($182M) has a higher market cap than SPRB($119M). SPRB YTD gains are higher at: 252.381 vs. GUTS (-35.437). SPRB has higher annual earnings (EBITDA): -48.11M vs. GUTS (-98.85M). SPRB has higher revenues than GUTS: SPRB (1.3M) vs GUTS (17K).
GUTSSPRBGUTS / SPRB
Capitalization182M119M153%
EBITDA-98.85M-48.11M205%
Gain YTD-35.437252.381-14%
P/E RatioN/AN/A-
Revenue17K1.3M1%
Total Cash22.3MN/A-
Total Debt61.7MN/A-
TECHNICAL ANALYSIS
Technical Analysis
GUTSSPRB
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
GUTS
Daily Signal:
Gain/Loss:
SPRB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QBEIF13.05N/A
N/A
QBE Insurance Group Ltd.
VENZF0.07N/A
N/A
Venzee Technologies Inc.
LSFG49.01N/A
N/A
Lifestore Financial Group, Inc.
MFGHF35.00N/A
N/A
Mainfreight Ltd.
PXPHF6.52N/A
N/A
Pexip Hldg ASA

GUTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GUTS has been loosely correlated with RCKT. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if GUTS jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GUTS
1D Price
Change %
GUTS100%
-5.00%
RCKT - GUTS
33%
Loosely correlated
-2.04%
UNCY - GUTS
32%
Poorly correlated
-6.59%
NEVPF - GUTS
31%
Poorly correlated
N/A
CRBU - GUTS
30%
Poorly correlated
-2.67%
SPRB - GUTS
29%
Poorly correlated
-3.48%
More

SPRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with NEVPF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRB
1D Price
Change %
SPRB100%
-3.48%
NEVPF - SPRB
61%
Loosely correlated
N/A
IMRX - SPRB
52%
Loosely correlated
+0.28%
MLEC - SPRB
51%
Loosely correlated
+2.01%
GNFT - SPRB
39%
Loosely correlated
+2.54%
IMCR - SPRB
37%
Loosely correlated
+1.55%
More